SLFN11 and adenocarcinoma: In contrast, SLFN11 is not overexpressed in neuroendocrine prostate cancer patients treated with platinum, and it has remained lower than CRPC with adenocarcinoma histology [69], indicating that SLFN11 upregulation in response to platinum-based chemotherapy is specific to prostatic adenocarcinoma.